CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B7-H3 在肿瘤中的免疫调控作用
英文原题：B7-H3 immunoregulatory roles in cancer.
查看英文原题
B7-H3 immunoregulatory roles in cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
B7同源蛋白3（B7-H3，也称CD276）是B7家族免疫检查点，在多种人类癌症中异常且持续表达，其过表达与不良预后相关。B7-H3可在多种细胞上表达，并促进免疫逃逸，具体表现为阻碍T细胞浸润并促进CD8+ T细胞耗竭。B7-H3活性升高还会促使巨噬细胞向促肿瘤的2型（M2）表型极化。此外，B7-H3活性增强会导致异常血管生成并促进缺氧，进而使肿瘤对常见免疫检查点抑制剂（ICI）治疗产生耐药；其机制之一是缺氧减少CD8+ T细胞向肿瘤区域募集。B7-H3的免疫抑制特性提示，靶向这一检查点可能成为癌症免疫治疗的有效策略。B7-H3可作为阻断性单克隆抗体（mAb）、联合治疗、嵌合抗原受体修饰T（CAR-T）细胞和双特异性抗体的靶点。
展开英文摘要原文
B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of B7 family that is aberrantly and consistently expressed in several human cancers, and its overexpression correlates with weak prognosis. B7-H3 is expressed on a number of cells, and it acts as a driver of immune evasion. This is mediated through hampering T cell infiltration and promoting exhaustion of CD8 + T cells. Increased B7-H3 activity also promotes macrophage polarity toward pro-tumor type 2 (M2) phenotype.
In addition, high B7-H3 activity induces aberrant angiogenesis to promote hypoxia, a result of which is resistance to common immune checkpoint inhibitor (ICI) therapy. This is mediated through the impact of hypoxia on dampening CD8 + T cell recruitment into tumor area.
The immunosuppressive property of B7-H3 offers insights into targeting this checkpoint as a desired approach in cancer immunotherapy. B7-H3 can be a target in blocking monoclonal antibodies (mAbs), combination therapies, chimeric antigen receptor-modified T (CAR-T) cells and bispecific antibodies.
论文信息
- 作者
- Mortezaee K
- 单位
- Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: keywan987@yahoo.com.Iran
- 文献类型
- 综述
- 期刊
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2023 Jul
- 原文标识
- PubMed 37196544 · DOI 10.1016/j.biopha.2023.114890